Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Bv improved survival for some Hodgkin patients

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Publish date:: September 28, 2018

Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.

Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.

Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.

Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.

Read the article.

Citation:

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

This Week's Must Reads

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,

Neoadjuvant immunotherapy combo produces high response rate in melanoma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Must Reads in Hodgkin Lymphoma

Survey quantifies COVID-19’s impact on oncology,

Early screening may halve breast cancer mortality in childhood cancer survivors,

Eczema may increase lymphoma risk, cohort studies suggest,

Cancer risk elevated in hidradenitis suppurativa patients,

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma,

Hematology and Oncology

Hematology and Oncology

Adding Bv improved survival for some Hodgkin patients

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

This Week's Must Reads

Must Reads in Hodgkin Lymphoma